1. Home
  2. ODD vs ESPR Comparison

ODD vs ESPR Comparison

Compare ODD & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ODD

ODDITY Tech Ltd.

HOLD

Current Price

$12.10

Market Cap

688.4M

Sector

N/A

ML Signal

HOLD

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$3.13

Market Cap

731.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ODD
ESPR
Founded
2018
2008
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
688.4M
731.9M
IPO Year
2022
2013

Fundamental Metrics

Financial Performance
Metric
ODD
ESPR
Price
$12.10
$3.13
Analyst Decision
Hold
Strong Buy
Analyst Count
11
4
Target Price
$41.00
$8.75
AVG Volume (30 Days)
1.3M
17.5M
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
60.71
EPS
N/A
N/A
Revenue
N/A
$403,135,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$22.92
$12.81
P/E Ratio
$16.73
N/A
Revenue Growth
N/A
21.31
52 Week Low
$10.80
$0.79
52 Week High
$79.18
$4.18

Technical Indicators

Market Signals
Indicator
ODD
ESPR
Relative Strength Index (RSI) 33.11 70.43
Support Level $10.80 $3.11
Resistance Level $16.04 $3.18
Average True Range (ATR) 0.84 0.02
MACD -0.11 -0.00
Stochastic Oscillator 8.79 28.57

Price Performance

Historical Comparison
ODD
ESPR

About ODD ODDITY Tech Ltd.

ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage. Geographically, the company generates majority revenue from United states followed by other countries and Israel.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Share on Social Networks: